Study In Asthma Control
Phase 4
Terminated
- Conditions
- Asthma
- Registration Number
- NCT00273026
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This study will compare patients treated with a marketed medication and those who continue with their usual care to assess the proportion of patients achieving well controlled asthma after 24 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 680
Inclusion Criteria
- documented clinical history of asthma and receiving regular maintenance therapy.
Exclusion Criteria
- Using oral/parenteral or depot corticosteroids within 12 weeks of visit 1.
- History of heavy smoking or substance abuse.
- Females who are pregnant or lactating.
- Required emergency room treatment for their asthma 12 weeks prior to Visit 1.
- Serious, uncontrolled, systemic disease that may make study participation unsafe or inappropriate in the opinion of the physician.
- Other medical criteria will be evaluated at the screening visit.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Percentage of patients achieving well-controlled asthma at the end of the treatment period.
- Secondary Outcome Measures
Name Time Method Percentage of patients achieving total asthma control as defined by the Canadian Asthma consensus guidelines at the end of the treatment period.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which ADVAIR improves asthma control compared to usual care?
How does the combination of fluticasone and salmeterol in ADVAIR compare to standard-of-care treatments in terms of clinical effectiveness for asthma management?
What biomarkers are associated with better asthma control outcomes in patients treated with ADVAIR versus standard therapies?
What are the known adverse events associated with ADVAIR use in adolescent and adult asthma patients, and how can they be managed effectively?
How does ADVAIR's efficacy in asthma control compare to other inhaled corticosteroid and long-acting beta agonist combinations in Phase 4 trials?
Trial Locations
- Locations (1)
GSK Investigational Site
🇨🇦Québec, Canada
GSK Investigational Site🇨🇦Québec, Canada